Thorsen Patricia, Jansen-van der Weide Martine C, Groenendaal Floris, Onland Wes, van Straaten Henrika L M, Zonnenberg Inge, Vermeulen Jeroen R, Dijk Peter H, Dudink Jeroen, Rijken Monique, van Heijst Arno, Dijkman Koen P, Cools Filip, Zecic Alexandra, van Kaam Anton H, de Haan Timo R
Department of Neonatology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands.
Pediatric Clinical Research Office, Woman-Child Department, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Pediatr Neurol. 2016 Jul;60:49-53. doi: 10.1016/j.pediatrneurol.2016.03.014. Epub 2016 Apr 1.
The Thompson encephalopathy score is a clinical score to assess newborns suffering from perinatal asphyxia. Previous studies revealed a high sensitivity and specificity of the Thompson encephalopathy score for adverse outcomes (death or severe disability). Because the Thompson encephalopathy score was developed before the use of therapeutic hypothermia, its value was reassessed.
The purpose of this study was to assess the association of the Thompson encephalopathy score with adverse short-term outcomes, defined as death before discharge, development of severe epilepsy, or the presence of multiple organ failure in asphyxiated newborns undergoing therapeutic hypothermia.
The study period ranged from November 2010 to October 2014. A total of 12 tertiary neonatal intensive care units participated. Demographic and clinical data were collected from the "PharmaCool" multicenter study, an observational cohort study analyzing pharmacokinetics of medication during therapeutic hypothermia. With multiple logistic regression analyses the association of the Thompson encephalopathy scores with outcomes was studied.
Data of 142 newborns were analyzed (male: 86; female: 56). Median Thompson score was 9 (interquartile range: 8 to 12). Median gestational age was 40 weeks (interquartile range 38 to 41), mean birth weight was 3362 grams (standard deviation: 605). All newborns manifested perinatal asphyxia and underwent therapeutic hypothermia. Death before discharge occurred in 23.9% and severe epilepsy in 21.1% of the cases. In total, 59.2% of the patients had multiple organ failure. The Thompson encephalopathy score was not associated with multiple organ failure, but a Thompson encephalopathy score ≥12 was associated with death before discharge (odds ratio: 3.9; confidence interval: 1.3 to 11.2) and with development of severe epilepsy (odds ratio: 8.4; confidence interval: 2.5 to 27.8).
The Thompson encephalopathy score is a useful clinical tool, even in cooled asphyxiated newborns. A score ≥12 is associated with adverse outcomes (death before discharge and development of severe epilepsy). The Thompson encephalopathy score is not associated with the development of multiple organ failure.
汤普森脑病评分是一种用于评估患有围产期窒息的新生儿的临床评分。先前的研究表明,汤普森脑病评分对不良结局(死亡或严重残疾)具有较高的敏感性和特异性。由于汤普森脑病评分是在治疗性低温疗法应用之前制定的,因此对其价值进行了重新评估。
本研究的目的是评估汤普森脑病评分与不良短期结局之间的关联,不良短期结局定义为接受治疗性低温疗法的窒息新生儿在出院前死亡、发生严重癫痫或出现多器官功能衰竭。
研究期间为2010年11月至2014年10月。共有12个三级新生儿重症监护病房参与。人口统计学和临床数据来自“PharmaCool”多中心研究,这是一项分析治疗性低温疗法期间药物药代动力学的观察性队列研究。通过多元逻辑回归分析研究汤普森脑病评分与结局之间的关联。
分析了142例新生儿的数据(男:共86例;女:56例)。汤普森评分中位数为9(四分位间距:8至12)。胎龄中位数为40周(四分位间距38至41),平均出生体重为3362克(标准差:605)。所有新生儿均表现为围产期窒息并接受了治疗性低温疗法。23.9%的病例在出院前死亡,21.1%的病例发生严重癫痫。总共有59.2%的患者出现多器官功能衰竭。汤普森脑病评分与多器官功能衰竭无关,但汤普森脑病评分≥12与出院前死亡(比值比:3.9;置信区间:1.3至11.2)以及严重癫痫的发生(比值比:8.4;置信区间:2.5至27.8)相关。
汤普森脑病评分是一种有用的临床工具,即使在接受低温治疗的窒息新生儿中也是如此。评分≥12与不良结局(出院前死亡和严重癫痫的发生)相关。汤普森脑病评分与多器官功能衰竭的发生无关。